Grodin Justin L, Tang W H Wilson
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk J3-4, Cleveland, OH, 44195, USA.
Curr Heart Fail Rep. 2013 Dec;10(4):331-40. doi: 10.1007/s11897-013-0154-8.
With the astounding morbidity and mortality associated with heart failure (HF), preventive approaches have been explored. Controlling hypertension to prevent HF is well-established, especially with sodium restriction and thiazide-based antihypertensive therapies showing potential advantages. Control of dyslipidemia with aggressive statin therapy is particularly beneficial in preventing HF in the setting of acute coronary syndrome. The HOPE study also established the benefit of ACE inhibitors in the prevention of HF in high-risk subjects. Meanwhile old data supporting tight glycemic control in preventing HF have not been confirmed, suggesting the complexity of diabetic cardiomyopathy. Avoiding tobacco use and other known cardiotoxins are likely helpful. While there has been substantial development in identifying biomarkers predicting future development of HF, therapeutic interdiction guided by biomarker levels have yet to be established, even though it offers hope in modulating the natural history of the development of HF in at-risk individuals.
鉴于心力衰竭(HF)所带来的惊人发病率和死亡率,人们一直在探索预防方法。控制高血压以预防HF已得到充分确立,特别是钠限制和基于噻嗪类的抗高血压疗法显示出潜在优势。在急性冠状动脉综合征的情况下,积极使用他汀类药物治疗控制血脂异常对预防HF特别有益。HOPE研究还证实了ACE抑制剂在预防高危人群HF方面的益处。与此同时,支持严格血糖控制以预防HF的旧数据尚未得到证实,这表明糖尿病性心肌病的复杂性。避免吸烟和其他已知的心脏毒素可能会有所帮助。虽然在识别预测HF未来发展的生物标志物方面有了很大进展,但即使生物标志物水平指导的治疗阻断为调节高危个体HF发展的自然病程带来了希望,其尚未确立。